We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced the signing of a collaboration agreement with ...
Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours.
Athenex, Inc. announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed into human clinical trials with the combination of oral topotecan and its proprietary P-glycoprotein (P-gp) inhibitor HM30181A.